Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

BackgroundFor patients with EGFR/HER2 exon20 insertions, platinum-containing double-drug chemotherapy is still the standard treatment method. First-generation TKIs have almost no therapeutic activity against EGFR exon 20 insertions. The efficacy of second-and third-generation TKIs is still controver...

Full description

Bibliographic Details
Main Authors: Jiaqi Li, Mengqing Xie, Ruiying Zhao, Huiping Qiang, Qing Chang, Jialin Qian, Haijiao Lu, Yinchen Shen, Yuchen Han, Chunxia Su, Tianqing Chu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
anti-angiogenic
immunotherapy
rare targets
EGFR20ins
HER2-20ins
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1357231/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1357231/full

Similar Items